AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21288774
Drug: NNRTI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNRTI and switch at 1000 copies per mL (NNRTI-low)
Trial: 21288774
Drug: NNRTI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNRTI and switch at 30,000 copies per mL (NNRTI-higher)
Trial: 21288774
Drug: Switching at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching at low threshold (1000 copies per mL)
Trial: 21288774
Drug: Switching at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching at higher threshold (30,000 copies per mL)
Trial: 18440181
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment strategies
Trial: 16081106
Drug: CBZ monotherapy
RxNorm normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBZ monotherapy
Trial: 10561191
Drug: G-CSF +
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF + EPO
Trial: 10831021
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg, administered orally)
Trial: 8922889
Drug: Half-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose aprotinin during surgery
Trial: 15587753
Drug: Cefcapene pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefcapene pivoxil (CFPN-PI; 450 mg/day)
Trial: 15587753
Drug: Cefteram pivoxil
RxNorm normalized name: cefteram pivoxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefteram pivoxil (CFTM-PI; 600 mg/day)
Trial: 3396372
Drug: Kinetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic treatment table
Trial: 29533115
Drug: Cholecalciferol 2,000
RxNorm normalized name: CHOLECALCIFEROL 2,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 2,000 IU daily with standard chemotherapy
Trial: 23423452
Drug: Etiquette-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiquette-based medicine (EtBM) behaviors performed by hospitalists
Trial: 23423452
Drug: Etiquette-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etiquette-based medicine scores
Trial: 21219197
Drug: Oral amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amino acid supplementation (4 g thrice a day) for 3 months
Trial: 11212974
Drug: Lisinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-20 mg)
Trial: 11117374
Drug: Enalapril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10-20 mg)
Trial: 1580094
Drug: Hydroxyethylrutosides 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylrutosides 500 mg (normal volunteers)
Trial: 1580094
Drug: Hydroxyethylrutosides 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylrutosides 1000 mg (patients with venous hypertension and diabetic microangiopathy)
Trial: 23332288
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2)
Trial: 22434360
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus cisplatin (75 mg/m2)
Trial: 15976248
Drug: Gargling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gargling with sodium azulene sulfonate (Azunol) 4 mg diluted with 100 mL tap water (40 microg/mL)
Trial: 11466189
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg fluticasone twice daily (group F)
Trial: 2604508
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of vitamin D during the first 3 months of LT4 treatment
Trial: 2604508
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin D during the first 3 months of LT4 treatment
Trial: 28385154
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of PZQ
Trial: 24518967
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg/day for 24 weeks)
Trial: 19754867
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment (twice weekly as maintenance treatment)
Trial: 19754867
Drug: Emollient vehicle
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient vehicle (standard treatment)
Trial: 19754867
Drug: 0.1% tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tacrolimus ointment (twice daily during OLP)
Trial: 7988813
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g intravenous infusion 15 minutes before ERCP
Trial: 2686711
Drug: Dilevalol twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol twice daily (N = 55)
Trial: 2686711
Drug: Dilevalol once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilevalol once daily (N = 40)
Trial: 20196640
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) with tamoxifen
Trial: 25858103
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) plus chemotherapy (CT)
Trial: 19878781
Drug: Nonsteroidal cream
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal cream (Promiseb Topical Cream)
Trial: 19878781
Drug: Desonide cream
RxNorm normalized name: Desonide Cream
DrugBank: Desonide sodium phosphate (DB15835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desonide cream 0.05%
Trial: 17514706
Drug: Routine information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine information preparation (Control)
Trial: 8733329
Drug: Amoxycillin/clavulanate bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate bid at a dose of 25/3.6mg/kg/day for 7 days
Trial: 8733329
Drug: Amoxycillin/clavulanate tid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate tid at a dose of 20/5mg/kg/day for 7 days
Trial: 2253536
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg orally four times a day
Trial: 7001486
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg protacine, 3-times daily, orally, for 10 days
Trial: 7001486
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg indomethacin, 3-times daily, orally, for 10 days
Trial: 7001486
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg protacine, 3-times daily, orally, for 18 days
Trial: 7001486
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oxyphenbutazone, 3-times daily, orally, for 18 days
Trial: 22453003
Drug: Acarbose (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (150 or 300 mg/day)
Trial: 19094763
Drug: Triptorelin 11.25
RxNorm normalized name: triptorelin 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 11.25 mg (one injection)
Trial: 19094763
Drug: Triptorelin 3.75
RxNorm normalized name: triptorelin 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 3.75 mg (three injections at 28-day intervals)
Trial: 15961681
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (0.16 micromol/kg min)
Trial: 12626215
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate 40 mg daily plus estradiol valerate 2 mg daily
Trial: 9589363
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oltipraz weekly
Trial: 9589363
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg oltipraz daily
Trial: 8927288
Drug: Alendronate 20
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 20 mg/day for six months
Trial: 6507769
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (sal)
Trial: 31213040
Drug: 5 mL/h
RxNorm normalized name: ropivacaine HCl/PF 0.2 % 5 mL/hour 500 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/h BEI + 10 mL/h PIEB
Trial: 31213040
Drug: 5 mL/h
RxNorm normalized name: ropivacaine HCl/PF 0.2 % 5 mL/hour 500 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/h BEI of levobupivacaine 0.125% plus fentanyl 1.45 µg/mL (standard group)
Trial: 30423955
Drug: Flavonoid supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavonoid supplementation (329 mg/day) with 45-minute walking (62.2 +/- 0.9% VO2max)
Trial: 30423955
Drug: Runners ingested
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runners ingested a double flavonoid dose (658 mg/day) and ran for 2.5 h (69.2 +/- 1.2% VO2max)
Trial: 26164110
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CT) plus pharmacotherapy
Trial: 20335369
Drug: CERA 6.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERA 6.3 μg/kg
Trial: 20335369
Drug: CERA 9
RxNorm normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CERA 9 μg/kg
Trial: 20335369
Drug: CERA 12
RxNorm normalized name: MIRCERA 120mcg/0.3mL Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CERA 12 μg/kg
Trial: 20335369
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (6.75 μg/kg every 3 weeks or 2.25 μg/kg weekly)
Trial: 17926466
Drug: Leflunomide (LF)
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide (LF) 100 mg/day for 3 days then 20 mg/day for 6 months
Trial: 11943259
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 500 mg plus Vitamin E 400 IU, each twice daily (n=19)
Trial: 9794352
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 16 mg once daily for 8 weeks
Trial: 9794352
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 32 mg once daily for 8 weeks
Trial: 110184
Drug: RIF 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF 600 mg
Trial: 110184
Drug: RIF 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF 750 mg
Trial: 110184
Drug: RIF 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF 450 mg
Trial: 110184
Drug: RIF-EMB therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF-EMB therapy (300 mg INH and 15 mg EMB per kg)
Trial: 110184
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of chemotherapy after sputum conversion
Trial: 110184
Drug: RIF-INH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIF-INH therapy
Trial: 27628062
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2.0 mg) administered as three monthly doses followed by injections every 2 months
Trial: 25827058
Drug: Pioglitazone (PIO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO, 15 mg for 6 weeks, then 30 mg daily)
Trial: 24246211
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg daily plus celecoxib 200 mg daily (study group)
Trial: 24246211
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg daily alone (control group)
Trial: 21575919
Drug: Trandolapril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (4 mg, n=10)
Trial: 21575919
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg, n=10)
Trial: 21575919
Drug: Trandolapril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (2 mg) + Verapamil (180 mg, n=10)
Trial: 19627355
Drug: Tin-containing fluoride
RxNorm normalized name: stannous fluoride Oral Gel [Gel-Tin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tin-containing fluoride solutions (400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Trial: 19627355
Drug: Tin-containing fluoride
RxNorm normalized name: stannous fluoride Oral Gel [Gel-Tin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tin-containing fluoride solutions (1,400 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Trial: 19627355
Drug: Tin-containing fluoride
RxNorm normalized name: stannous fluoride Oral Gel [Gel-Tin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tin-containing fluoride solutions (2,100 ppm Sn2+, 1,500 ppm F-, pH 4.5)
Trial: 19660515
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control group (no treatment)
Trial: 19627355
Drug: Test solutions
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test solutions without demineralization (twice daily)
Trial: 16417535
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at doses up to 2000 mg/day
Trial: 8193987
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone 1.5 mg/kg infused over 5 mins
Trial: 7936333
Drug: Intravenous propafenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propafenone
Trial: 2822924
Drug: Intraarticular deferoxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular deferoxamine 100 mg
Trial: 29913174
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (60 mg, initiated at 13-25 weeks' gestation)
Trial: 23294659
Drug: Resonant breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resonant breathing biofeedback training (5 weekly sessions)
Trial: 16005384
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg of D‐amphetamine
Trial: 12404670
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (paroxetine and citalopram)
Trial: 2158260
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 (40 mg oral dose)
Trial: 335584
Drug: PUFA preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA preparation
Trial: 26223506
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent A (20% aluminum chloride hexahydrate)
Trial: 26223506
Drug: Topical agent
RxNorm normalized name: topical agent combination no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agent B (1% aluminum acetate)
Trial: 23223947
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ropivacaine and 2 μg sufentanil in 30 mL 0.9% saline (Group B)
Trial: 23223947
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ropivacaine in 30 mL 0.9% saline (Group C)
Trial: 23223947
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg sufentanil in 30 mL 0.9% saline (Group D)
Trial: 23223947
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.9% saline (Group A)
Trial: 18180761
Drug: Brief intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intensive cognitive-behavioral therapy (CBT)
Trial: 19335435
Drug: Normal controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal controls (no treatment)
Trial: 11693075
Drug: Pharmaceutical Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical Care (PhC)
Trial: 9383924
Drug: Innovative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative treatment applications and strategies to integrate research and practice
Trial: 7523480
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody based kits
Trial: 7523480
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies specific for the holohormone (anti-alpha beta)
Trial: 30039790
Drug: Single quadrant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single quadrant injection technique (Group S)
Trial: 30039790
Drug: Two quadrants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two quadrants injection technique (Group C)
Trial: 30905173
Drug: Acupuncture (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (twice weekly for 8 weeks)
Trial: 26365445
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anti-hypertensive treatment for 12 weeks)
Trial: 21175845
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) bolus abciximab
Trial: 9146775
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg effervescent
Trial: 9146775
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg effervescent
Trial: 9146775
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg capsules
Trial: 8190296
Drug: Entacapone (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (acute and chronic administration)
Trial: 6138053
Drug: Oxazepam 30
RxNorm normalized name: oxazepam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 30 mg
Trial: 28335745
Drug: Lidocaine/prilocaine (25/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine (25/25 mg, 10 cm2, application duration: 60 min)
Trial: 23314743
Drug: LCI699 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (0.5 mg b.i.d. for 14 days, then 1 mg b.i.d. for 15 days)
Trial: 23314743
Drug: Eplerenone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (50 mg b.i.d., up-titrated to 100 mg b.i.d. in 12/14 patients)
Trial: 23314743
Drug: Eplerenone (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (50-100 mg b.i.d.)
Trial: 23314743
Drug: LCI699 (0.5-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 (0.5-1 mg b.i.d.)
Trial: 22108151
Drug: Ezetimibe/simvastatin (10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (10/20 or 10/40 mg)
Trial: 22108151
Drug: Atorvastatin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10, 20, or 40 mg)
Trial: 22108151
Drug: Ezetimibe/simvastatin (10/20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (10/20-40 mg)
Trial: 22108151
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses (ezetimibe/simvastatin and atorvastatin)
Trial: 30939085
Drug: Hypnotic intervention
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic intervention
Trial: 15166915
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba special extract EGb 761 (2 x 120 mg/day for 7 days)
Trial: 9713935
Drug: diphtheria‐tetanus‐acellular pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphtheria‐tetanus‐acellular pertussis (dTap) vaccine
Trial: 9713935
Drug: diphtheria‐tetanus (dT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diphtheria‐tetanus (dT) vaccine
Trial: 2840652
Drug: Metoclopramide (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (doses adjusted to each individual case)
Trial: 20677606
Drug: 5.0% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0% lignocaine 75 mg